The conversation among women on or considering GLP-1s has shifted in the last year. Where the question was once “should I start Ozempic,” it’s increasingly “should I start now, or wait for retatrutide?”
The question is worth taking seriously. Retatrutide is the most advanced of a new class of agents called multi-receptor agonists — drugs that activate not just the GLP-1 receptor (like semaglutide) or GLP-1 and GIP receptors (like tirzepatide), but a third receptor as well. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. Its late-stage trial data is genuinely impressive. And it’s coming.
Whether you should wait, however, depends on factors that the trial data alone doesn’t answer.
What the trials actually show
The TRIUMPH-1 trial (Eli Lilly), published in The New England Journal of Medicine in January 2026, was the pivotal Phase 3 study of retatrutide for obesity in non-diabetic patients. The headline numbers:
- ✓ Average weight loss at 48 weeks: 24.2% at the high dose (12 mg weekly)
- ✓ Comparison: tirzepatide’s SURMOUNT-1 produced 20.9%; semaglutide’s STEP-1 produced 14.9%
- ✓ Approximately 60% of participants achieved ≥20% weight loss; ~25% achieved ≥30% (an outcome category that didn’t exist in earlier GLP-1 trials because no drug produced it consistently)
- ✓ Improvement in liver fat, blood pressure, lipids, and inflammatory markers at magnitudes proportional to or somewhat greater than tirzepatide
The drug also reduced visceral fat (the metabolically dangerous fat around organs) more aggressively than its predecessors. Body composition substudies showed a slightly more favorable fat-to-lean-mass loss ratio than tirzepatide, though still with substantial lean mass loss at the higher doses.
FDA approval is widely anticipated in Q4 2026 or Q1 2027. Pricing is expected to land in the premium range of the current GLP-1 market — roughly $1,500-2,000/month at list price.
What the trials don’t answer
Three big unknowns sit alongside the impressive efficacy data:
One: discontinuation behavior. Retatrutide is too new to have post-discontinuation data of any meaningful size. Whether the post-drug regain curve is similar to, better than, or worse than semaglutide/tirzepatide is currently a hypothesis, not a finding. There is no reason to expect it to be dramatically different — the underlying biology of appetite recovery and ghrelin rebound is largely independent of which receptors the original drug targeted — but we don’t know yet.
Two: long-horizon safety. The glucagon agonism component of retatrutide is the novel piece. Glucagon receptor activation has theoretical metabolic benefits but also some theoretical risks (cardiovascular load, hepatic effects). The trial data so far is reassuring on these, but post-marketing surveillance data — the kind that revealed the gallbladder issues with semaglutide several years after FDA approval — doesn’t exist yet.
Three: bone density and muscle effects at greater absolute loss. The faster and deeper the weight loss, the higher the lean mass and bone mineral density risk (see our bone density piece). Retatrutide produces deeper loss than current GLP-1s. The substudy data on body composition is okay but not definitive — and the women losing 30%+ of body weight are likely to face larger absolute lean mass and bone deficits to rebuild post-discontinuation.
The actual decision framework
For a woman currently making the “start now or wait” calculation, the relevant variables are not really about which drug is “best.”
They’re about:
How much time you have. Waiting 12-18 months for retatrutide approval is a long time if you’re currently 240 pounds with metabolic comorbidities accelerating. Cardiovascular risk doesn’t pause for drug pipelines. For many women, the right answer is to start on currently-available treatment and revisit when retatrutide is available.
What you’d switch to if you switched. Retatrutide is not currently expected to be FDA-approved as a switch-over from existing GLP-1 treatment in the absence of inadequate response. Insurance coverage will almost certainly require step-therapy through current approved options first. The realistic path is: start on tirzepatide or semaglutide now, switch to retatrutide later if appropriate.
What you mean by “better.” If “better” means more weight loss at the maximum dose, retatrutide will be better. If “better” means more durable post-discontinuation outcomes, we don’t know yet — and there’s reasonable grounds to suspect the same maintenance window will apply regardless of which drug delivered the loss.
The hard truth: the next-generation drug doesn’t change the post-drug maintenance problem this site is built to solve. Whatever drug gets you to your target weight, the 18-month window after discontinuation will still be where maintenance is won or lost. The drug is the first half of the work; the protocol is the second half. That hasn’t changed and is unlikely to change.
The next-generation drug doesn’t change the post-drug maintenance problem. Whatever drug gets you to your target weight, the 18-month window after is where maintenance is won or lost.
What about for women already on a current GLP-1?
If you’re currently on semaglutide or tirzepatide and getting good results, switching to retatrutide when it becomes available is not obviously the right move — even if your weight loss has plateaued. The reasons:
First, the side effect profile resets when you switch drugs. The first 8-12 weeks of any new GLP-1 class drug come with elevated GI side effects. Whatever stability you’ve achieved on your current drug, you give up to titrate up on a new one.
Second, plateaus on current GLP-1s often respond to behavioral intervention, not drug switching. The plateau may reflect that your body has found a new set point at the appropriate weight for the protocol you’re running. Switching to a more aggressive drug might break the plateau, but might also produce loss past a point that’s sustainable.
Third, your insurance coverage, supply stability, and cost are known on your current drug. With retatrutide, all three will be different and probably worse for the first 12-24 months post-launch.
The case for switching is strongest when: (a) you’ve had inadequate response on current treatment, (b) you tolerated tirzepatide poorly relative to its weight loss benefit, or (c) you specifically need the deeper liver fat or visceral fat reductions that retatrutide produces.
The maintenance question, asked differently
One implication of the retatrutide trials that doesn’t get discussed enough: the deeper the weight loss the drug produces, the more important the maintenance protocol becomes.
A woman who loses 25% of her body weight on retatrutide has more to maintain than a woman who lost 15% on semaglutide. The absolute pounds of regain that constitute “substantial” are larger. The bone mineral density and lean mass deficits are larger. The metabolic adaptation is potentially deeper.
For the woman planning to use a triple-agonist when it’s available, the maintenance protocol should be more, not less, structured than for previous-generation drugs. The cost of failure goes up with the loss magnitude.
This is why we’re building the WeWontRegain protocol now — not just for semaglutide and tirzepatide users, but for the women who will, in 2027 and beyond, be discontinuing 25-30% body weight loss from the next generation of agents and facing the same maintenance window with even higher stakes.
The protocol is independent of which drug delivered the loss. Whether your discontinuation is from semaglutide today or retatrutide in 2027, the post-drug 18 months work the same way. Schedule a free consult →
What you can do right now
If you’re a woman planning a future GLP-1 protocol — whether you’re starting now or waiting for retatrutide:
Start the resistance training base now. Whatever weight loss you eventually undertake, you’ll preserve more lean mass and bone if you have a resistance training practice already established when treatment begins.
Establish the dietary pattern now. The Mediterranean-pattern eating discussed in our diet piece works whether you’re pre-treatment, mid-treatment, or post-treatment. Building this pattern now means it’s already in place when treatment ends.
Identify a clinical team for post-discontinuation now. The biggest predictor of outcome in the 2026 literature is whether you have structured support running during the post-discontinuation window. Knowing who that team is before you need them is a small lift now that pays off substantially later.
This is what the WeWontRegain 1:1 protocol does, and what we work on with members regardless of where they are in the medication arc.
Whether retatrutide is in your future or not, the maintenance work belongs to you. We’re ready when you are. Talk to us free for 15 minutes →
Sources & methodology note
Primary references: TRIUMPH-1 retatrutide Phase 3 trial (NEJM, January 2026); SURMOUNT-1 tirzepatide (NEJM, 2022); STEP-1 semaglutide (NEJM, 2021). FDA approval timeline based on publicly stated company guidance and historical drug approval patterns; actual timing may vary. Nothing in this piece constitutes medical advice.